Phase 1 Evaluation of GSK5764227 in Patients with Advanced Neoplasms

The primary objective of this Phase 1 study is to evaluate the safety and tolerability of **GSK5764227** in participants with advanced **solid tumors**. This is clinically relevant as it aims to determine the potential adverse effects and establish a safe dosage range for this investigational drug, which is crucial for further clinical development and potential therapeutic use in oncology.

The clinical trial involves a total of **204 participants** diagnosed with **neoplasms**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected without targeting any vulnerable populations. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion and exclusion criteria.

The clinical trial is designed to evaluate the safety and efficacy of a new investigational product in participants with **neoplasms**. This study is a Phase 1 trial, which is typically the first stage of testing in human subjects and focuses on assessing the safety profile of the investigational product. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the investigators know which treatment the participants are receiving, thereby minimizing bias. The estimated recruitment start date is August 29, 2025, with the trial expected to conclude by March 19, 2027, indicating an overall trial duration of approximately 19 months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a comprehensive assessment, including medical history review and necessary diagnostic tests. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are scheduled to monitor the participants' health, assess the investigational product's effects, and ensure adherence to the study protocol. The end-of-study visit will occur after the final treatment cycle, where a thorough evaluation will be conducted to gather final safety and efficacy data.

The expected length of participant involvement in the study is contingent upon the treatment regimen and the individual's response to the investigational product. Participants may be withdrawn from the study early if they experience significant adverse effects, fail to comply with the study protocol, or if the investigator deems it in the participant's best interest. The study is conducted in accordance with ethical guidelines and regulatory requirements, ensuring the safety and well-being of all participants throughout the trial.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be provided.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included in the data. As such, these aspects cannot be detailed in the context of this clinical trial description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on August 29, 2025, with an estimated completion date of March 19, 2027. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the therapeutic benefits of the intervention under investigation. The trial's design will likely incorporate validated scales and laboratory tests to measure outcomes, although specific tools and instruments are not specified. The efficacy data will be analyzed to determine the intervention's impact on the targeted medical condition, ensuring that the findings are robust and clinically relevant.